Metastatic hormone-sensitive prostate cancer (mHSPC) is deadly, with a reported median survival of less than 5 years. Historically, androgen deprivation therapy (ADT) has been the standard of care. The development of new therapeutic options, however, has significantly improved survival.
In this ReCAP, Dr William Oh discusses the essential role that ADT still plays in mHSPC, the importance of recently approved chemoimmunotherapies and small-molecule androgen inhibitors, and how to choose the most appropriate treatment strategy for patients.
Medscape © 2019 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Metastatic Hormone-Sensitive Prostate Cancer - Medscape - Sep 09, 2019.
Comments